Costimulation of T cells for tumor immunity.
Tumor specific antigens can be demonstrated on many neoplasms by immunization and challenge experiments; however, these antigens do not normally elicit a sufficiently strong immune response to prevent tumor growth in immunocompetent hosts. Recent studies have demonstrated that efficient activation of T cells requires costimulation of the CD28 receptor via the B7 molecule on antigen-presenting cells. Inadequate costimulation of tumor-reactive T cells may contribute to the fact that antigenic tumors are not normally rejected by the immune system, and weak anti-tumor immune responses may be amplified by upregulation of CD28 triggering.
Chen
L
L
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121.
Linsley
P S
PS
Hellström
K E
KE
D000818:Animals; D000951:Antigens, Neoplasm; D018122:B7-1 Antigen; D018106:CD28 Antigens; D006801:Humans; D008213:Lymphocyte Activation; D008954:Models, Biological; D009374:Neoplasms, Experimental / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm; D018122:B7-1 Antigen; D018106:CD28 Antigens